Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs
Shots:
- The US FDA has approved Orlynvah (sulopenem etzadroxil & probenecid) to treat uUTIs in adult women, specifically addressing infections caused by E.coli, Klebsiella pneumoniae, or Proteus mirabilis, particularly when there are few or no other oral therapy available
- Approval was based on two pivotal P-III studies (SURE 1 & REASSURE) that assessed the safety & efficacy of Orlynvah vs ciprofloxacin (SURE 1) & Augmentin (REASSURE)
- The SURE 1 trial found that Orlynvah was superior to ciprofloxacin for fluoroquinolone-resistant infections, while REASSURE demonstrated both non-inferiority & statistical superiority to Augmentin among patients susceptible to that antibiotic. Both trials indicated well-tolerability
Ref: Iterum | Image: Iterum
Related News:- European Patent Office (EPO) Grants Approval to Biogen’s Tecfidera Patent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com